Resverlogix completes patient recruitment in Phase 2 ASSERT clinical study

Resverlogix (TSX:RVX) has completed patient enrolment in the Phase 2 ASSERT clinical study of its lead cholesterol drug RVX-208, five months ahead of schedule.

“At this rate we could be seeing the final dosed patient in May, 2010,” CEO Donald McCaffrey said in a statement.

“In the second half of 2010, we look forward to being able to share the results from the trial, which will mark yet another major milestone in the development of our oral therapeutic for the treatment of atherosclerosis,” he added.

The primary objective of the 280-patient study is to determine if RVX-208 will produce an increase in plasma apolipoprotein A-I (ApoA-l) levels, compared with placebo, after three months of dosing.  The secondary objectives are to examine the safety and tolerability of RVX-208, to compare the dose and time response relationships for ApoA-l over time, and to examine key reverse cholesterol markers involved with HDL functioning.